More recently, molecular phenotyping has demonstrated that mucinous ovarian carcinomas have similarities with gastrointestinal malignancies, including frequent KRAS mutation, and preclinical data suggest this subtype of ovarian cancer may respond to agents such as 5-FU and oxaliplatin used in the treatment of colorectal cancer [33,34]. The gene discussed is KRAS; the disease is ovarian mucinous adenocarcinoma.